Next 10 |
2024-06-14 14:38:51 ET Summary Avidity Biosciences, Inc.'s FORTITUDE trial of AOC 1020 in treating FSHD showed promising reductions in DUX4 gene expression and improvements in muscle function. The trial reported favorable safety and tolerability, with no serious adverse events or ...
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
2024-05-13 17:52:17 ET More on Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate ...
2024-05-13 17:06:07 ET Gainers: Harrow ( HROW ) +15% . Fulcrum Therapeutics ( FULC ) +7% . Allogene Therapeutics ( ALLO ) +6% . Infinera Corporation ( INFN ) +6% . Voyager Therapeutics ( VYGR ) +5% . Losers: Akoya BioScie...
2024-05-13 10:38:01 ET Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript May 13, 2024, 08:00 AM ET Company Participants Alex Sapir - CEO and President Alan Musso - CFO Paul Bruno - SVP of Business and Corporate Development Iain Fraser - SVP o...
2024-05-13 10:09:30 ET More on Sanofi, Fulcrum Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Biggest stock movers today: ARM, ZK...
2024-05-13 07:22:58 ET More on Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript Fulcrum hits 52-week high as CEO buys shares Seeking Alpha’s Quant Rating on Fulcrum Therapeutics Historical earnings data for Fulcru...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourt...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...